{"id":5046,"date":"2011-07-06T10:45:05","date_gmt":"2011-07-06T14:45:05","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=5046"},"modified":"2011-07-06T10:45:05","modified_gmt":"2011-07-06T14:45:05","slug":"sanofi-rib-x-to-collaborate-on-new-types-of-antibiotics","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=5046","title":{"rendered":"Sanofi, Rib-X to Collaborate on New Types of Antibiotics"},"content":{"rendered":"<figure id=\"attachment_898\" aria-describedby=\"caption-attachment-898\" style=\"width: 200px\" class=\"wp-caption alignright\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/09\/MRSA_CDC.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-898\" title=\"MRSA_CDC\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/09\/MRSA_CDC.jpg\" alt=\"MRSA bacteria (CDC)\" width=\"200\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/09\/MRSA_CDC.jpg 200w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/09\/MRSA_CDC-150x150.jpg 150w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a><figcaption id=\"caption-attachment-898\" class=\"wp-caption-text\">Scanning electron micrograph image of MRSA bacteria (Janice Haney Carr, Centers for Disease Control and Prevention)<\/figcaption><\/figure>\n<p>The global pharmaceutical firm <a href=\"http:\/\/en.sanofi.com\/binaries\/20110706_RIBX_en_tcm28-32980.pdf\">Sanofi<\/a> has agreed to jointly develop new antibiotic technology with the biotechnology company <a href=\"http:\/\/www.rib-x.com\/news_and_events\/release_2011_07_06\">Rib-X Pharmaceuticals<\/a> in New Haven, Connecticut. The agreement includes an option for Sanofi to license the technology from Rib-X that treats resistant pathogens.<\/p>\n<p>Rib-X&#8217;s RX-04 program is developing new types of antibiotics aimed at drug-resistant pathogens, which the company says has been shown effective in animal models. RX-04 targets bacterial ribosomes, an internal cell component that synthesizes proteins from amino acids and RNA. Rib-X says recent data confirm that this approach directly impacts ribosome functions by interfering with protein synthesis.<\/p>\n<p>Under the agreement, Rib-X will receive $10 million in an upfront payment, as well as up to an additional $9 million in near-term research-based milestones. The company will also be eligible for further payments for the achievement of research, preclinical, regulatory and commercial milestones. The agreement could result in up to $86 million in development and regulatory milestones, with commercial milestones exceeding $100 million.<\/p>\n<p>Sanofi will be able to develop multiple products under this agreement. Except for those assets licensed to Sanofi through the agreement, Rib-X retains its rights to the platform that developed its technology and its future programs. Rib-X retains a co-promotion option in the United States on one of the molecules coming from the collaboration.<\/p>\n<p>The <a href=\"http:\/\/www.cdc.gov\/drugresistance\/about.html\">Centers for Disease Control<\/a> notes that people infected with drug-resistant organisms are more likely to have longer and more expensive hospital stays, and may be more likely to die as a result of the infection. When the drug of choice for treating their infection fails to work, they require treatment with second- or third-choice drugs that may be less effective, more toxic, and more expensive.<\/p>\n<p>Read more: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=4319\">Sanofi, Glenmark Sign Autoimmune Antibody License Deal<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The global pharmaceutical firm Sanofi has agreed to jointly develop new antibiotic technology with the biotechnology company Rib-X Pharmaceuticals in New Haven, Connecticut. The agreement includes an option for Sanofi to license the technology from Rib-X that treats resistant pathogens. Rib-X&#8217;s RX-04 program is developing new types of antibiotics aimed at drug-resistant pathogens, which the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[31,21,84,64,27],"class_list":["post-5046","post","type-post","status-publish","format-standard","hentry","category-ventures","tag-biomedical","tag-biotech","tag-licensing","tag-life-sciences","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/5046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5046"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/5046\/revisions"}],"predecessor-version":[{"id":5050,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/5046\/revisions\/5050"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}